Please assess the completion status of the following clinical trial:

Trial Title: Organoids From Metastases of Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with metastatic prostate cancer~* Patient having a biopsy programmed as part of his care.~* Patient having a biopsy programmed as part of hiscare.~* Patient with sufficient tumor volume after imaging data review by the radiologist to guarantee a sufficient quantity of material for the diagnosis of biopsy and additional material for the study.~* INR \<1.5; Platelets \> 50000 / μL~Exclusion Criteria:~* Patient under age of 18 years.~* Patient under Plavix or Effient or Ticlid without possibility of suspension for 5 days, low molecular weight heparin without possibility of suspension of the dose before the intervention, or Fondaparinux without possibility of suspension, or ReoPro without possibility of suspension for 24h and aPTT \<50s and ACT \<150s, or Integrilin or Aggrastat or Argatroban without possibility of suspension 4 H before the intervention, or Angiomax without possibility of suspending 2H to 3H if CrCL\> 50 mL / min or 3H to 5h if CrCL \<50 mL / min before the intervention or and Pradaxa without possibility of suspension 2 to 3 days if CrCL\> 50 mL / min or 3 to 5 days if CrCL \<50 mL / min before the procedure~* Patient under desmopressin acetate (DDAVP)~* Patient with HIV or Hepatitis C positive or Hepatitis B infection, defined by either a detection of the HBs antigen or the presence of anti HBc antibodies without HBs antibody detectable.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Extended biopsy

Based on this trial design, predict the completion outcome and termination type (if applicable).